Department of Pathology, University of Washington, 300 9th Avenue, Seattle, WA 98104, USA.
Nat Rev Neurol. 2011 May 10;7(6):308-9. doi: 10.1038/nrneurol.2011.66.
Biomarker development is important to the therapeutic imperative for neurodegenerative diseases, as biomarkers hold transformative promise for the design and conduct of clinical trials and, ultimately, for medical management of these diseases. Some of this promise is now being realized in Alzheimer disease, and progress in Parkinson disease is accelerating.
生物标志物的开发对于神经退行性疾病的治疗至关重要，因为生物标志物为临床试验的设计和实施提供了变革性的前景，最终为这些疾病的医疗管理提供了前景。其中一些前景已经在阿尔茨海默病中得到了实现，而帕金森病的进展正在加速。
